News | Heart Failure | November 02, 2015

Cardionomic Raises $20 Million to Develop Neuromodulation for Heart Failure

Therapy tackles the root cause of acute decompensated heart failure to reduce readmissions

November 2, 2015 — Medical device developer Cardionomic Inc. announced that it has received $20 million in Series A financing. Investors include New Enterprise Associates (NEA), the Cleveland Clinic, Greatbatch Inc. and others.

The company will use the funding to continue development of an innovative neuromodulation therapy for acute decompensated heart failure (ADHF), a condition in which patients with heart failure experience fluid accumulation in their lungs and other tissues, making it difficult for them to breathe, sleep and function.

ADHF leads to more than 1 million U.S. hospital admissions and to healthcare costs exceeding $10 billion annually, according to the American Heart Association (AHA). Furthermore, nearly one-quarter of ADHF patients are readmitted to the hospital within one month of treatment and half are re-hospitalized within six months. With hospitals facing financial penalties for readmissions within 30 days, the high rate of re-hospitalization of ADHF patients is a growing concern.

“Current ADHF approaches, all of which use drug therapies, inadequately treat the condition and have not improved over the past decades,” said William T. Abraham, M.D., Cardionomic’s chief medical officer and one of the world’s leading heart failure physicians. “The Cardionomic therapy targets the primary cause of worsening heart failure, namely decreased myocardial contractility.” Increased contractility improves the heart’s pumping performance.

Cardionomic’s therapy selectively stimulates cardiac nerve branches, which safely improves contractility and addresses the disorder’s root cause instead of focusing on relief of symptoms, which is the current standard of care. The therapy is expected to be delivered to the patient upon admission and to remain in place for one to three days before it is removed.

“This targeted increase in contractility rebalances hemodynamics to normalize blood flow to organs, such as the kidneys and brain, and restores kidney function to eliminate fluids. It thereby treats both the root cause of ADHF and its symptoms,” said Abraham.

For more information: www.cardionomicinc.com

Related Content

Videos | Heart Failure

The University of Maryland Medical Center (UMMC) announced the first successful transplant of a genetically modified pig ...

Home January 11, 2022
Home
Feature | Heart Failure | By Dave Fornell, DAIC Editor

January 10, 2022 — The University of Maryland School of Medicine (UMSOM) and the University of Maryland Medical Center ...

Home January 10, 2022
Home
News | Heart Failure

December 16, 2021 — MVP Health Care and The University of Vermont Health Network recently announced their joint Medicare ...

Home December 16, 2021
Home
News | Heart Failure

November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...

Home November 19, 2021
Home
News | Heart Failure

November 17, 2021 — Canagliflozin, a medication used to treat type 2 diabetes, was found to greatly improve symptoms and ...

Home November 17, 2021
Home
News | Heart Failure

November 10, 2021 — Ancora Heart Inc., a company developing a novel therapy to address heart failure, announced results ...

Home November 10, 2021
Home
News | Heart Failure

November 2, 2021 — Cardionomic Inc. announce initial U.S. enrollment in its global Cardiac Pulmonary Nerve Stimulation ...

Home November 02, 2021
Home
News | Heart Failure

October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling ...

Home October 27, 2021
Home
News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
Subscribe Now